WordNet
- the 20th letter of the Roman alphabet (同)t
- an agranulocytic leukocyte that normally makes up a quarter of the white blood cell count but increases in the presence of infection (同)lymph cell
- a tough youth of 1950s and 1960s wearing Edwardian style clothes (同)Teddy boy
PrepTutorEJDIC
- tritiumの化学記号
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. BおよびTリンパ球の正常な発生 normal b and t lymphocyte development
- 2. 特発性CD4陽性リンパ球減少症 idiopathic cd4 lymphocytopenia
- 3. 大顆粒T細胞リンパ球性白血病の臨床症状、病理学的特徴、および診断 clinical manifestations pathologic features and diagnosis of t cell large granular lymphocyte leukemia
- 4. T細胞受容体シグナル伝達 t cell receptor signaling
- 5. 成人T細胞性白血病/リンパ腫の臨床症状、病理学的特徴、および診断 clinical manifestations pathologic features and diagnosis of adult t cell leukemia lymphoma
English Journal
- Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection.
- Sunshine JE1, Larsen BB2, Maust B2, Casey E2, Deng W2, Chen L2, Westfall DH2, Kim M2, Zhao H2, Ghorai S2, Lanxon-Cookson E2, Rolland M3, Collier AC4, Maenza J4, Mullins JI5, Frahm N6.
- Journal of virology.J Virol.2015 Oct 15;89(20):10303-18. doi: 10.1128/JVI.01876-15. Epub 2015 Jul 29.
- To understand the interplay between host cytotoxic T-lymphocyte (CTL) responses and the mechanisms by which HIV-1 evades them, we studied viral evolutionary patterns associated with host CTL responses in six linked transmission pairs. HIV-1 sequences corresponding to full-length p17 and p24 gag were
- PMID 26223634
- Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
- Koster BD1, de Gruijl TD, van den Eertwegh AJ.
- Current opinion in oncology.Curr Opin Oncol.2015 Sep 8. [Epub ahead of print]
- PURPOSE OF REVIEW: In this review, we focus on the recent findings and future challenges in cancer treatment with immune checkpoint inhibitors.RECENT FINDINGS: Major progress has been made in recent years as the first immune checkpoint inhibitors are approved by the US Food and Drug Administration f
- PMID 26352539
- Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.
- Kawano K1, Tsuda N1, Waki K2, Matsueda S3, Hata Y3, Ushijima K1, Itoh K3, Yamada A2, Kamura T1.
- Cancer science.Cancer Sci.2015 Sep;106(9):1111-7. doi: 10.1111/cas.12729. Epub 2015 Jul 22.
- A feasibility study was performed to evaluate the immunological efficacy and safety of a personalized peptide vaccine (PPV) for cervical cancer patients who have received platinum-based chemotherapy. A total of 24 patients with standard chemotherapy-resistant cervical cancer, including 18 recurrent
- PMID 26122553
Japanese Journal
- 人工抗原提示細胞を用いた抗腫瘍CTLの誘導と抗原の同定
- 臨床免疫・アレルギー科 62(6), 645-648, 2014-12
- NAID 40020294486
- P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma
- Cancer Immunology, Immunotherapy 63(5), 479-489, 2014-05
- NAID 120005464870
- The Present Status of Therapeutic Cancer Vaccines
- 順天堂醫事雑誌 60(5), 469-469, 2014
- NAID 130005064591
Related Links
- Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3. Aidoo M, Lalvani A, Gilbert SC, Hu JT, Daubersies P, Hurt N, Whittle HC, Druihle P, Hill AV. Molecular Immunology ...
- An epitope, also known as antigenic determinant, is the part of an antigen that is recognized by the immune system, specifically by antibodies, B cells, or T cells. The part of an antibody that recognizes the epitope is called a paratope. Although ...
Related Pictures
★リンクテーブル★
| リンク元 | 「Tリンパ球エピトープ」「T-cell epitope」 |
| 関連記事 | 「T」「lymphocyte」「T lymphocyte」 |
「Tリンパ球エピトープ」
「T-cell epitope」
「T」
「lymphocyte」
- 同
- lymphocytes＆development